Introduction: Psoriasis is a chronic inflammatory disease that may also involve nails. Unfortunately, topical treatments available are limited and often responsible for side effects and/or lack of compliance due to the necessary prolonged use to see results. Intralesional treatment instead is often unwanted or unaccepted by patients. Lack of efficacy is, moreover, always a possible outcome. Novel modalities for the therapy of nail psoriasis are thus needed and always welcomed. Case Presentation: We then aimed to develop a topical 2% tofacitinib formulation expected to facilitate nail penetration and use in patients with recalcitrant forms of nail psoriasis unwilling to accept other routes of administration of treatment besides the topical one. Conclusion: These preliminary data, despite the use in 3 patients only, suggest a potential use of topical tofacitinib 2% for nail psoriasis. Further studies on bigger groups are however necessary to confirm the present encouraging results and establish the effectiveness and safety also in more severe cases or in the pediatric population.
Topical Tofacitinib as Effective Therapy in Patients with Plaque Psoriasis Responsive to Systemic Drugs but with Resistant Nail Psoriasis / R. Berbert Ferreira, S. Berbert Ferreira, A.C. Neves Neto, S.M. Caparroz-Assef, L. Brichta, G. Damiani, M. Iorizzo. - In: SKIN APPENDAGE DISORDERS. - ISSN 2296-9195. - 9:5(2023 Oct), pp. 380-384. [10.1159/000531119]
Topical Tofacitinib as Effective Therapy in Patients with Plaque Psoriasis Responsive to Systemic Drugs but with Resistant Nail Psoriasis
G. DamianiPenultimo
;
2023
Abstract
Introduction: Psoriasis is a chronic inflammatory disease that may also involve nails. Unfortunately, topical treatments available are limited and often responsible for side effects and/or lack of compliance due to the necessary prolonged use to see results. Intralesional treatment instead is often unwanted or unaccepted by patients. Lack of efficacy is, moreover, always a possible outcome. Novel modalities for the therapy of nail psoriasis are thus needed and always welcomed. Case Presentation: We then aimed to develop a topical 2% tofacitinib formulation expected to facilitate nail penetration and use in patients with recalcitrant forms of nail psoriasis unwilling to accept other routes of administration of treatment besides the topical one. Conclusion: These preliminary data, despite the use in 3 patients only, suggest a potential use of topical tofacitinib 2% for nail psoriasis. Further studies on bigger groups are however necessary to confirm the present encouraging results and establish the effectiveness and safety also in more severe cases or in the pediatric population.| File | Dimensione | Formato | |
|---|---|---|---|
|
000531119.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
259.85 kB
Formato
Adobe PDF
|
259.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




